Clinical trials: de Novo Coronary Lesions
Coronary Artery Disease
Study Safety and Performance of the Biomime Stent in Patients With Single, De Novo, Non-Complex Coronary Lesions
1.) Indigenously developed and designed BioMimeTM is a predictably safe \& efficacious 3rd generation drug eluting stent (DES) with a propensity to minimize vascular injury by use of an intelligent mix of ultra-low strut…
- Trial name
- meriT-1 (NCT01507519)
- Testing
- Sirolimus Eluting Coronary Stent System (Biomime)
- Where
- India
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Meril Life Sciences Pvt. Ltd.
Coronary Atherosclerosis of Native Coronary Artery, Bifurcation Lesions: de Novo Lesions of the Main and Side Branch of Native Coronary Artery
Prospective, Single Blind, Rand Controlled Study to Evaluate the Safety & Effectness of Tryton Side Branch Stent Used With DES Treatmt of de Novo Bifurcation Lesions in MB & SB in Native Coronaries
The Tryton Side Branch Stent System has been designed to address the procedural difficulty surrounding treatment of bifurcation lesions and to ensure patency of the side branch with similar performance capabilities (e.g.…
- Trial name
- TRYTON (NCT01258972)
- Testing
- Tryton Side Branch Stent with main branch DES, POBA
- Where
- United States
- Volunteers
- 133 people, healthy volunteers welcome
- Sponsor
- Tryton Medical, Inc.